

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Baillie Gifford Worldwide Health Innovation Fund - Class B EUR Accumulation Shares

Accumulation Shares- ISIN IE00BGGJJB67. Baillie Gifford Worldwide Health Innovation Fund ("the Fund") is a sub-fund of Baillie Gifford Worldwide Funds PLC ("the Company" or "the PRIIP"). The Fund is managed by **Baillie Gifford Investment Management (Europe) Limited** ("the Manager"), which is a subsidiary of Baillie Gifford Overseas Limited [and forms part of the Baillie Gifford Group]. The Manager is the manufacturer of the PRIIP, and is authorised in Ireland and regulated by the Central Bank of Ireland. For more information on this PRIIP, please visit www.bailliegifford.com or call at 00-353-1-241-7156. Central Bank of Ireland is responsible for supervising Baillie Gifford Investment Management (Europe) Limited in relation to this Key Information Document. This PRIIP is authorised in Ireland.

Date of Production 14/02/2024

What is this product?

Type

Baillie Gifford Worldwide Health Innovation Fund ("the Fund") is a sub-fund of Baillie Gifford Worldwide Funds PLC (the Company). The Fund is managed by Baillie Gifford Investment Management (Europe) Limited. The Company is an open-ended investment company with variable capital organised under the laws of Ireland as a public limited company pursuant to the Companies Acts and the UCITS Regulations and is managed by the Manager.

Term

The Fund does not have a fixed maturity. All the shares in the Fund may be redeemed by the Company in certain circumstances details of which are outlined in the Prospectus including if so determined by the Directors of the Company, following consultation with the Manager. As such, the Manager may not unilaterally terminate the Fund.

Objectives

The Fund aims to provide capital growth over the long term by investing primarily in a global equity portfolio from companies engaged in the healthcare industry and that promotes better healthcare outcomes by driving real change for patients and the healthcare system and evidence care about patients. The Fund will invest at least 90% in shares of companies in global equities in the healthcare industry which are innovative in their focus on areas such as diagnostics, treatment and prevention and contribute to solving a problem for the healthcare system in a method that cares about patients. Companies are assessed qualitatively on the solution the company is providing to an existing healthcare issue, its ability to democratise access to healthcare solutions and its engagement with its patients. The Fund will comply with the Investment Managers policy on assessing breaches of the United Nations Global Compact Principles for Business. The Fund will be concentrated by the number of stocks held but diversified across a range of healthcare themes. The Fund is actively managed and no index is used for the purposes of determining or constraining the composition of the Fund's portfolio. The Fund's performance (after deduction of costs) is measured against the MSCI ACWI Index. The Fund seeks to materially outperform the index. The return of the Fund is dependent on the performance of the underlying assets. Income will be re-invested. No further shares will be purchased but the reinvestment will be reflected in the price of your existing accumulation shares. You can sell some or all of your shares on any day on which banks in Ireland are open for business by contacting the Transfer Agent by phone or post. The Fund's assets are held through the Company's Depositary, which is Brown Brothers Harriman Trustee Services (Ireland) Limited. To obtain further and other practical information, including prices, and documentation please see the Other Relevant Information section of this document. This Key Information Document describes the Fund only, the Prospectus and the annual and interim reports and accounts are prepared for the Company rather than the Fund. The assets of the Fund are segregated from other funds in the Company. This means that the assets of one fund cannot be used to meet the liabilities of another fund. You may at any time switch all or some of your shares in the Fund for shares in any other fund of the Company and may obtain further information about this from the conversion of shares section of the Prospectus.

Intended retail investor

The Fund is suitable for all investors seeking a fund that aims to deliver long-term capital growth with a thematic focus on investing in health and healthcare companies. The Fund considers sustainability preferences through a minimum proportion of sustainable investments and the qualitative consideration of principal adverse impacts using an exclusionary approach. Investors should be prepared to bear losses. The Fund is compatible for mass market distribution. The Fund may not be suitable for investors concerned about short-term volatility and performance and investing for less than five years. The Fund does not offer capital protection.

What are the risks and what could I get in return?

Risk Indicator

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

1	2	3	4	5	6	7
---	---	---	---	---	---	---

Lower riskHigher risk

The risk indicator assumes you keep the product for a minimum of 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

We have classified this product as 5 out of 7, which is a medium-high risk class.

This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the capacity of Baillie Gifford Investment Management (Europe) Limited to pay you.

Risk raised by exposure to emerging markets, including China and foreign currencies. If charges exceed income then excess taken from capital.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Page 1 of 3

Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 10 years. Markets could develop very differently in the future.

Recommended holding period: Example Investment:		5 years EUR 10,000	
		If you exit after 1 year	If you exit after 5 years
Scenarios			
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress	What you might get back after costs	EUR 1,390	EUR 920
	Average return each year	-86.08%	-37.96%
Unfavourable	What you might get back after costs	EUR 5,360	EUR 1,500
	Average return each year	-46.43%	-31.56%
Moderate	What you might get back after costs	EUR 11,210	EUR 16,670
	Average return each year	12.08%	10.76%
Favourable	What you might get back after costs	EUR 21,150	EUR 32,600
	Average return each year	111.53%	26.66%

The stress scenario shows what you might get back in extreme market circumstances.

This product cannot be easily cashed in. If you exit the investment earlier than the recommended holding period you do not have a guarantee.

Unfavourable This type of scenario occurred for an investment between September 2021 and March 2023.

Moderate This type of scenario occurred for an investment between April 2014 and April 2019.

Favourable This type of scenario occurred for an investment between February 2016 and February 2021.

What happens if Baillie Gifford Investment Management (Europe) Limited is unable to pay out?

Any default by Baillie Gifford Investment Management (Europe) Limited will not materially affect the value of your shares. However, a default by the Fund or any of the underlying holdings could affect the value of your investment. The legal relationship is between an investor and the Company, any direct holding of these is not covered by any investor compensation schemes in relation to either Baillie Gifford Investment Management (Europe) Limited or the Company.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over Time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0 % annual return). For the other holding period we have assumed the product performs as shown in the moderate scenario.
- That your EUR 10,000.00 has been invested.

	If you exit after 1 year	If you exit after 5 years
Total costs	EUR 86	EUR 582
Annual cost impact (*)	0.9%	0.9% each year

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 9.9% before costs and 9.0% after costs.

Composition of Costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	Neither Baillie Gifford Investment Management (Europe) Limited nor the Fund charge an entry fee.	EUR 0
Exit costs	Neither Baillie Gifford Investment Management (Europe) Limited nor the Fund charge an exit fee for this product, but the person selling you the product may do so.	EUR 0
Ongoing costs taken each year		
Management fees and other administrative or operating costs	0.65% of the value of your investment per year. This is an estimate based on actual costs over the last year.	EUR 65
Transaction costs	0.21% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	EUR 21
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	EUR 0

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

The recommended holding period of 5 years has been selected as equity investments should be seen as long-term investments. However there is no minimum (or maximum) holding period for the Fund. This Fund may not be appropriate for investors who plan to withdraw their money within five years. The actual risk can vary significantly if you cash in at an early stage and you may get back less. There are no exit fees charged but the person selling you the product may do so.

How can I complain?

If you have a complaint about the person advising on or selling the product you will need to provide the details to the person who advised you or sold you the product. If you have any complaints about the product or the conduct of the Manufacturer, complaints can be made by contacting the Manufacturer's Client Relations Manager at Baillie Gifford Investment Management (Europe) Limited, 4/5 School House Lane East, Dublin 2, by emailing BGE@bailliegifford.com or by calling 00-353-1-241-7156.

Other relevant information

This Key Information Document has been produced by Baillie Gifford Investment Management (Europe) Limited. You can obtain further information on the Fund, as well as documents which we are legally required to make available such as the Prospectus, past performance up to 10 years, the latest share prices and the latest annual and interim reports from Baillie Gifford or by visiting the website at www.bailliegifford.com. All such documents are available in English on paper and are free of charge on request. Tax laws in Ireland may have an impact on your own tax position. Performance scenarios are calculated on a monthly basis and these calculations are available on the Fund's website at www.bailliegifford.com. The person advising on or selling the product may have to provide you with additional information as required by their financial regulator or national law. The most up to date version of this Key Information Document can be found on the Company's website at www.bailliegifford.com. The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus. If you are in any doubt about the action you should take, you should seek independent financial advice.

Annex – For investors in Switzerland

Baillie Gifford Investment Management (Europe) Limited is a wholly owned subsidiary of Baillie Gifford Overseas Limited. Baillie Gifford Investment Management (Europe) Limited commenced regulatory business on 1 January 2019 and provides investment management and advisory services for European (excluding UK but including Switzerland) clients. With effect from 1 April 2022, Baillie Gifford Investment Management (Europe) Limited was appointed as a UCITS management company to Baillie Gifford Worldwide Funds plc. Baillie Gifford Investment Management (Europe) Limited is incorporated in Ireland as a limited liability company under the Companies Act 2014, with registration number 625892 and authorised and regulated by the Central Bank of Ireland as an AIFM in accordance with Regulation 7 of the AIFM Regulations to provide management of portfolios of investments, including Individual Portfolio Management and Non-Core Services, with its registered office at 4/5 School House Lane East, Dublin 2, D02 N279, Ireland. Baillie Gifford Investment Management (Europe) Limited has established a representative office in Zurich, Switzerland for the purposes of marketing and client service pursuant to Art. 58 of the Federal Act on Financial Institutions, with registered office at Bahnhofstr. 10 / Börsenstr. 18, CH - 8001, Zurich, Switzerland. As a representative office, it does not have authority to commit Baillie Gifford Investment Management (Europe) Limited.

The extract prospectus and the Key Information Documents for Switzerland, the articles of association, the extract annual and semi-annual report in English, and further information can be obtained free of charge from the representative in Switzerland: UBS Fund Management (Switzerland) AG, Aeschenvorstadt 1, 4002 Basel. The Swiss paying agent is UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich. The last share prices can be found on www.fundinfo.com.